Tris(4-azidophenyl)methanol - a novel and multifunctional thiol protecting group

The novel tris(4-azidophenyl)methanol, a multifunctionalisable aryl azide, is reported. The aryl azide can be used as a protecting group for thiols in peptoid synthesis and can be cleaved under mild reaction conditions via a Staudinger reduction. Moreover, the easily accessible aryl azide can be functionalised via copper-catalysed cycloaddition reactions, providing additional opportunities for materials chemistry applications.Peer reviewe

Confirmation of the topology of the Wendelstein 7-X magnetic field to better than 1:100,000

Fusion energy research has in the past 40 years focused primarily on the tokamak concept, but recent advances in plasma theory and computational power have led to renewed interest in stellarators. The largest and most sophisticated stellarator in the world, Wendelstein 7-X (W7-X), has just started operation, with the aim to show that the earlier weaknesses of this concept have been addressed successfully, and that the intrinsic advantages of the concept persist, also at plasma parameters approaching those of a future fusion power plant. Here we show the first physics results, obtained before plasma operation: that the carefully tailored topology of nested magnetic surfaces needed for good confinement is realized, and that the measured deviations are smaller than one part in 100,000. This is a significant step forward in stellarator research, since it shows that the complicated and delicate magnetic topology can be created and verified with the required accuracy.EURATOM 633053U.S. Department of Energy DE-AC02-09CH1146

Codebook and documentation of the panel study 'Labour Market and Social Security' (PASS) : Volume I: Introduction and overview. Wave 2 (2007/2008)

"The panel study 'Labour Market and Social Security' (PASS), established by the Institute for Employment Research (IAB), is a new dataset for labour market, welfare state and poverty research in Germany, creating a new empirical basis for the scientific community and for policy advice. This Datenreport provides an overview of the second survey wave, for which 12,487 individuals were interviewed in 8,429 households between December 2007 and July 2008. 10,114 individuals and 7,342 households were interviewed for the second time in the context of PASS. The spectrum of questions and the design of PASS are intended to close gaps in the existing stock of data. PASS has three main characteristics that extend analysis potential beyond that of the Federal Employment Agency's administrative data: 1. The panel takes the household context into account - including the situation before and after receipt of Unemployment Benefit II. 2. The panel is complete in that it covers all groups of persons and all employment biographies, not only people in dependent employment, unemployed people and those in need of assistance. The dataset also provides information on the status during phases of economic inactivity, self-employment or employment as civil servants. 3. The panel collects additional or significantly more detailed data on relevant characteristics such as attitudes, employment potential or job-search behaviour." (Author's abstract, IAB-Doku) ((en)) Additional Information Questionnaires of the second wave. Here you can find the German version. Further information about the panel study "Labour Market and Social Security".IAB-Haushaltspanel, Datengewinnung, Erhebungsmethode, Stichprobe, Panel - Methode, Datenaufbereitung

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme

BACKGROUND A novel budesonide orodispersible tablet (BOT) has been proven effective in adult patients with active eosinophilic oesophagitis (EoE) in a 6-week placebo-controlled trial (EOS-1). AIMS To report the efficacy of an open-label induction treatment with BOT in a large prospective cohort of EoE patients within the EOS-2 study. METHODS Patients with clinico-histological active EoE were treated with BOT 1 mg BID for 6 weeks. The primary endpoint was clinico-histological remission (≤2 points on numerical rating scales [0-10] each for dysphagia and odynophagia, and peak eosinophil count <16 eos/mm$^{2}$ hpf (corresponds to <5 eos/hpf)). Further study endpoints included clinical and histological remission rates, change in the EEsAI-PRO score, change in peak eosinophil counts, and deep endoscopic remission using a modified Endoscopic Reference Score. RESULTS Among 181 patients enrolled, 126 (69.6%) achieved clinico-histological remission (histological remission 90.1%, clinical remission 75.1%). The mean peak eosinophil counts decreased by 283 eos/mm$^{2}$ hpf (i.e., by 89.0%). Mean EEsAI-PRO score decreased from baseline by 29 points and deep endoscopic remission was achieved in 97 (53.6%) patients. The majority of patients judged tolerability as good or very good (85.6%) and compliance was high (96.5%). Local candidiasis was suspected in 8.3% of patients; all were of mild severity, resolved with treatment and none led to premature withdrawal from the study. CONCLUSIONS In this large prospective trial, a 6-week open-label treatment with BOT 1 mg BID was highly effective and safe in achieving clinico-histological remission of active EoE and confirmed the results of the placebo-controlled EOS-1 trial

Codebuch und Dokumentation des 'Panel Arbeitsmarkt und soziale Sicherung' (PASS) : Welle 2 (2007/2008)

"The panel study 'Labour Market and Social Security' (PASS), established by the Institute for Employment Research (IAB), is a new dataset for labour market, welfare state and poverty research in Germany, creating a new empirical basis for the scientific community and for policy advice. This "Datenreport" written in German provides an overview of the second survey wave, for which 12,487 individuals were interviewed in 8,429 households between December 2007 and July 2008. 10,114 individuals and 7,342 households were interviewed for the second time in the context of PASS. The spectrum of questions and the design of PASS are intended to close gaps in the existing stock of data. PASS has three main characteristics that extend analysis potential beyond that of the Federal Employment Agency's administrative data: 1. The panel takes the household context into account - including the situation before and after receipt of Unemployment Benefit II. 2. The panel is complete in that it covers all groups of persons and all employment biographies, not only people in dependent employment, unemployed people and those in need of assistance. The dataset also provides information on the status during phases of economic inactivity, self-employment or employment as civil servants. 3. The panel collects additional or significantly more detailed data on relevant characteristics such as attitudes, employment potential or job-search behaviour." (Author's abstract, IAB-Doku) ((en)) The english version of this "Datenreport" you can find here: http://fdz.iab.de/187/section.aspx/Publikation/k100607a04 Additional Information Hier finden Sie Band I des Datenreports: Einführung und Überblick Hier finden Sie Band II: Codebuch Haushaltsdatensatz Hier finden Sie Band III: Codebuch Personendatensatz Hier finden Sie Band IV: Codebuch Spelldaten, Registerdaten und Gewichte Fragebögen der 2. Welle Hier finden Sie die englische Version des Datenreports. Weitere Informationen zum Panel "Arbeitsmarkt und Soziale Sicherung".IAB-Haushaltspanel, Datengewinnung, Erhebungsmethode, Stichprobe, Panel - Methode, Datenaufbereitung

Intranasal delivery of bone marrow derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease

In view of the rapid preclinical development of cell-based therapies for neurodegenerative disorders, traumatic brain injury, and tumors, the safe and efficient delivery and targeting of therapeutic cells to the central nervous system is critical for maintaining therapeutic efficacy and safety in the respective disease models. Our previous data demonstrated therapeutically efficacious and targeted delivery of mesenchymal stem cells (MSCs) to the brain in the rat 6-hydroxydopamine model of Parkinson’s disease (PD). The present study examined delivery of bone marrow derived MSCs, macrophages, and microglia to the brain in a transgenic model of PD ((Thy1)-h[A30P] αS) and an APP/PS1 model of Alzheimer’s disease (AD) via intranasal application (INA). INA of microglia in naïve BL/6 mice led to targeted and effective delivery of cells to the brain. Quantitative PCR analysis of eGFP DNA showed that the brain contained the highest amount of eGFP-microglia (up to 2.1x104) after INA of 1x106 cells, while the total amount of cells detected in peripheral organs did not exceed 3.4x103. Seven days after INA, MSCs expressing eGFP were detected in the olfactory bulb (OB), cortex, amygdala, striatum, hippocampus, cerebellum, and brainstem of (Thy1)-h[A30P] αS transgenic mice, showing predominant distribution within the OB and brainstem. INA of eGFP-expressing macrophages in 13 month-old APP/PS1 mice led to delivery of cells to the OB, hippocampus, cortex, and cerebellum. Both, MSCs and macrophages contained Iba-1-positive population of small microglia-like cells and Iba-1-negative large rounded cells showing either intracellular Amyloid beta (macrophages in APP/PS1 model) or α-Synuclein (MSCs in (Thy1)-h[A30P] αS model) immunoreactivity. Here we show, for the first time, intranasal delivery of cells to the brain of transgenic PD and AD mouse models. Additional work is needed to determine the optimal dosage (single treatment regimen or repeated administrations) to achieve functional improvement in these mouse models with intranasal microglia/macrophages and MSCs